Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-04-25 4:40 pm Purchase | 13D | Spyre Therapeutics Inc. SYRE | Fairmount Funds Management LLC | 4,508,579 11.17% | 3,672,120 (+439.01%) | View |
| 2024-04-23 6:22 pm Sale | 13G | Spyre Therapeutics Inc. SYRE | Avoro Capital Advisors LLC | 1,839,138 5.1% | -286,459 (-13.48%) | View |
| 2024-03-11 08:19 am Purchase | 13G | Spyre Therapeutics Inc. SYRE | FMR LLC | 6,584,175 18.213% | 377,724 (+6.09%) | View |
| 2024-02-14 8:47 pm Purchase | 13G | Spyre Therapeutics Inc. SYRE | Venrock Healthcare Capital Partners III L.P. | 3,734,514 9.99% | 3,734,514 (New Position) | View |
| 2024-02-14 4:51 pm Unchanged | 13G | Spyre Therapeutics Inc. SYRE | Nantahala Capital Management LLC | 0 0% | 0 (Unchanged) | View |
| 2024-02-14 4:37 pm Purchase | 13G | Spyre Therapeutics Inc. SYRE | EcoR1 Capital LLC | 887,076 2.5% | 887,076 (New Position) | View |
| 2024-02-14 4:27 pm Unchanged | 13G | Spyre Therapeutics Inc. SYRE | PERCEPTIVE ADVISORS LLC | 2,606,679 7.2% | 0 (Unchanged) | View |
| 2024-02-14 4:21 pm Unchanged | 13G | Spyre Therapeutics Inc. SYRE | BAKER BROS. ADVISORS LP | 0 0% | 0 (Unchanged) | View |
| 2024-02-14 4:05 pm Purchase | 13G | Spyre Therapeutics Inc. SYRE | COMMODORE CAPITAL LP | 1,934,084 5.4% | 100,000 (+5.45%) | View |
| 2024-02-14 3:51 pm Purchase | 13G | Spyre Therapeutics Inc. SYRE | Logos Global Management LP | 150,000 0.4% | 150,000 (New Position) | View |
| 2024-02-14 2:07 pm Unchanged | 13G | Spyre Therapeutics Inc. SYRE | Rock Springs Capital Management LP | 0 0% | 0 (Unchanged) | View |
| 2024-02-14 09:08 am Purchase | 13G | Spyre Therapeutics Inc. SYRE | Avoro Capital Advisors LLC | 2,125,597 5.9% | 2,125,597 (New Position) | View |
| 2024-02-14 08:56 am Sale | 13G | Spyre Therapeutics Inc. SYRE | Deep Track Capital LP | 2,184,440 6.03% | -5,073,616 (-69.90%) | View |
| 2024-02-14 07:02 am Purchase | 13G | Spyre Therapeutics Inc. SYRE | RTW INVESTMENTS LP | 2,232,760 6.2% | 2,232,760 (New Position) | View |
| 2024-02-13 6:46 pm Unchanged | 13G | Spyre Therapeutics Inc. SYRE | BCLS II Equity Opportunities LP | 0 0% | 0 (Unchanged) | View |
| 2024-02-13 5:28 pm Purchase | 13G | Spyre Therapeutics Inc. SYRE | SUVRETTA CAPITAL MANAGEMENT LLC | 412,395 1% | 412,395 (New Position) | View |
| 2024-02-13 4:48 pm Purchase | 13G | Spyre Therapeutics Inc. SYRE | Affinity Asset Advisors LLC | 653,409 1.81% | 653,409 (New Position) | View |
| 2024-02-13 09:39 am Purchase | 13G | Spyre Therapeutics Inc. SYRE | Polar Capital Holdings Plc | 500,000 1.05% | 500,000 (New Position) | View |
| 2024-02-12 12:03 pm Purchase | 13G | Spyre Therapeutics Inc. SYRE | FMR LLC | 6,206,451 13.065% | 2,420,574 (+63.94%) | View |
| 2024-02-09 10:20 am Purchase | 13G | Spyre Therapeutics Inc. SYRE | FMR LLC | 3,785,877 7.969% | 3,785,877 (New Position) | View |